Recombinant Yersinia pseudotuberculosis serotype IB Serine hydroxymethyltransferase (glyA)

What is Serine Hydroxymethyltransferase (SHMT) and what role does it play in Yersinia pseudotuberculosis?

Serine hydroxymethyltransferase (SHMT), encoded by the glyA gene, is a crucial enzyme (EC 2.1.2.1) that catalyzes the reversible conversion of L-serine to glycine. In Yersinia pseudotuberculosis, this enzyme plays a vital role in one-carbon metabolism and bacterial cell growth. The enzyme functions by transferring the hydroxymethyl group from serine to tetrahydrofolate, forming glycine and 5,10-methylene tetrahydrofolate, which is essential for nucleotide synthesis and amino acid metabolism. This process is fundamental to the bacterium's ability to proliferate and potentially contribute to its pathogenicity .

How does the structure of Y. pseudotuberculosis glyA compare with other bacterial species?

The Y. pseudotuberculosis serotype IB SHMT is a full-length protein of 417 amino acids. Its amino acid sequence shares varying degrees of homology with other bacterial SHMTs, though less than what is observed among closely related species. For instance, while not directly comparable to Y. pseudotuberculosis, the SHMT from Corynebacterium glutamicum shows 73% identity with Mycobacterium tuberculosis, 53% with Bacillus subtilis, and 48% with E. coli homologues . The Y. pseudotuberculosis SHMT contains conserved functional domains typical of this enzyme family, including binding sites for pyridoxal 5'-phosphate cofactor and substrate interaction regions. The protein sequence begins with "MLKREMNIAD YDADLWRAME..." and continues through a series of conserved regions that form the active site and structural framework of the enzyme .

What is known about the expression and regulation of the glyA gene in Y. pseudotuberculosis?

While the search results don't provide direct information about glyA regulation in Y. pseudotuberculosis specifically, parallels can be drawn from other bacterial systems. In numerous bacterial species, glyA is subject to complex transcriptional control mechanisms. For example, in E. coli, the glyA gene is preceded by inverted repeats and multiple promoter regions, indicating highly regulated transcriptional control . It's reasonable to hypothesize that Y. pseudotuberculosis may employ similar regulatory mechanisms for glyA expression, potentially including transcription factors responsive to carbon source availability, amino acid levels, and one-carbon metabolite concentrations. Research on glyA expression in Y. pseudotuberculosis would likely reveal condition-dependent regulation related to growth phase, nutrient availability, and environmental stressors.

What are the optimal storage and handling conditions for Recombinant Y. pseudotuberculosis SHMT?

The recombinant Y. pseudotuberculosis serotype IB SHMT requires careful handling to maintain its structural integrity and enzymatic activity. The protein should be stored at -20°C for regular storage, while extended storage should be at either -20°C or -80°C. Repeated freezing and thawing cycles should be strictly avoided as they can significantly degrade protein quality and activity. For working aliquots that need to be accessed frequently, storage at 4°C is recommended, but only for up to one week .

The shelf life of the recombinant protein varies depending on its formulation: in liquid form, it typically maintains stability for approximately 6 months when stored at -20°C or -80°C, whereas the lyophilized form extends the shelf life to about 12 months at the same temperatures. These storage parameters are crucial for maintaining the protein's structural integrity and enzymatic activity for experimental purposes .

What is the recommended protocol for reconstituting lyophilized Recombinant Y. pseudotuberculosis SHMT?

For optimal reconstitution of lyophilized recombinant Y. pseudotuberculosis SHMT, the following methodological approach is recommended:

• First, briefly centrifuge the vial containing the lyophilized protein to ensure all material is at the bottom of the container.

• Reconstitute the protein using deionized sterile water to achieve a final concentration between 0.1-1.0 mg/mL.

• For long-term storage, add glycerol to a final concentration of 5-50% (with 50% being the standard recommendation).

• Aliquot the reconstituted protein into smaller volumes to minimize freeze-thaw cycles.

• Store these aliquots at -20°C or -80°C for extended preservation .

This protocol helps maintain protein stability and activity by protecting against structural degradation during freeze-thaw cycles and providing a suitable buffer environment for the enzyme.

How can researchers verify the purity and activity of Recombinant Y. pseudotuberculosis SHMT?

Researchers can employ multiple complementary approaches to verify both the purity and enzymatic activity of recombinant Y. pseudotuberculosis SHMT:

Purity Assessment:

• SDS-PAGE analysis: The recombinant protein should show >85% purity as indicated by a predominant band at approximately 46.5 kDa .

• Western blotting: Using anti-His antibodies for detection if the recombinant protein contains a histidine tag.

• Mass spectrometry: For more precise molecular weight determination and confirmation of protein identity.

Activity Verification:

• Spectrophotometric assay: Measuring the conversion of L-serine to glycine in the presence of tetrahydrofolate (THF).

• Comparative assay: Testing against known standards of SHMT activity. For context, purified SHMT from other sources has demonstrated specific activity of approximately 31.0 μmol min⁻¹(mg of protein)⁻¹ with L-serine as substrate .

• Substrate specificity: Confirming the enzyme can also use L-threonine as a substrate (though at lower efficiency) as is typical for SHMTs from various sources. With L-threonine, activity levels around 1.3 μmol min⁻¹(mg of protein)⁻¹ would be expected .

These methods collectively provide a comprehensive assessment of the recombinant protein's quality and functional characteristics.

What are the recommended methods for cloning and expressing the glyA gene from Y. pseudotuberculosis?

Based on successful approaches used for similar enzymes, the following methodology is recommended for cloning and expressing the glyA gene from Y. pseudotuberculosis:

Cloning Strategy:

• Design primers based on the known Y. pseudotuberculosis glyA sequence (full length: 1,305 nucleotides) with appropriate restriction sites (e.g., BamHI and SalI) for directional cloning.

• Amplify the glyA gene using high-fidelity PCR from genomic DNA of Y. pseudotuberculosis serotype IB.

• Digest the PCR product and expression vector (e.g., pQE30 for His-tagged expression) with appropriate restriction enzymes.

• Ligate the digested PCR product into the vector and transform into a suitable E. coli strain (e.g., E. coli M15) .

Expression Protocol:

• Culture the recombinant E. coli strain in LB medium with appropriate antibiotics.

• Induce protein expression with IPTG when the culture reaches mid-log phase (OD₆₀₀ of 0.6-0.8).

• Harvest cells after 4-6 hours of induction and lyse using standard methods.

• Purify the His-tagged SHMT using Ni-NTA affinity chromatography .

This approach has been successful for expressing similar enzymes and should yield active recombinant Y. pseudotuberculosis SHMT with high purity.

How can researchers measure the enzymatic activity of Recombinant Y. pseudotuberculosis SHMT?

Researchers can employ several established methodologies to accurately measure the enzymatic activity of recombinant Y. pseudotuberculosis SHMT:

Spectrophotometric Assay:

• Prepare a reaction mixture containing L-serine (or L-threonine), tetrahydrofolate (THF), and appropriate buffer (typically at pH 7.5).

• Add purified recombinant SHMT to initiate the reaction.

• Monitor the formation of 5,10-methylene-THF spectrophotometrically at 340 nm.

• Calculate the specific activity in μmol min⁻¹(mg of protein)⁻¹.

HPLC-Based Method:

• Conduct the enzymatic reaction as above.

• Terminate the reaction at defined time points.

• Quantify the produced glycine using HPLC with appropriate derivatization.

• Plot the reaction kinetics to determine enzymatic parameters.

Coupled Enzyme Assay:

• Link the SHMT reaction to a secondary enzyme system that produces a detectable signal.

• For example, couple with methylenetetrahydrofolate dehydrogenase to oxidize the 5,10-methylene-THF to 10-formyl-THF.

• Monitor NADH production at 340 nm.

Based on studies with similar enzymes, researchers should expect specific activities of approximately 31.0 μmol min⁻¹(mg of protein)⁻¹ with L-serine and about 1.3 μmol min⁻¹(mg of protein)⁻¹ with L-threonine .

What methods are available for studying the structure-function relationship of Y. pseudotuberculosis SHMT?

Several sophisticated methodological approaches can be employed to elucidate the structure-function relationships of Y. pseudotuberculosis SHMT:

Site-Directed Mutagenesis:

• Identify conserved amino acid residues through sequence alignment with well-characterized SHMTs.

• Generate point mutations using PCR-based mutagenesis techniques.

• Express and purify the mutant proteins.

• Assess the impact on enzymatic activity, substrate binding, and cofactor interaction.

X-ray Crystallography:

• Purify the recombinant protein to >95% homogeneity.

• Screen for crystallization conditions using commercial kits.

• Optimize conditions that yield diffraction-quality crystals.

• Collect diffraction data and solve the crystal structure.

• Analyze the active site architecture and substrate binding pockets.

Molecular Dynamics Simulations:

• Using the crystal structure or a homology model, perform MD simulations.

• Analyze protein flexibility, conformational changes, and substrate interactions.

• Identify potential allosteric sites and communication pathways within the protein.

Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS):

• Expose the protein to deuterium-containing buffer.

• Analyze the rate and extent of hydrogen-deuterium exchange.

• Identify regions of structural flexibility and solvent accessibility.

These approaches provide complementary insights into how structure dictates function in Y. pseudotuberculosis SHMT and can guide rational design of inhibitors or protein engineering efforts.

How does Y. pseudotuberculosis SHMT contribute to bacterial pathogenesis and virulence?

The contribution of SHMT to Y. pseudotuberculosis pathogenesis involves multiple interconnected metabolic and physiological pathways. While direct evidence for Y. pseudotuberculosis is limited in the search results, insights from related bacterial systems suggest several mechanisms:

Metabolic Contribution to Pathogenesis:

• One-carbon metabolism supported by SHMT is crucial for nucleotide synthesis and DNA replication, directly supporting bacterial proliferation during infection.

• SHMT activity provides glycine for peptidoglycan synthesis, contributing to cell wall integrity under host-induced stress conditions.

• The enzyme potentially supports amino acid homeostasis in nutrient-limited host environments.

Virulence Connection:

• In Tannerella forsythia, the glyA gene has been directly associated with pathogenesis, with a particularly strong correlation to aggressive periodontitis cases (57.14% prevalence in aggressive periodontitis versus 0% in milder forms) .

• The knockout of glyA in various bacterial species results in growth defects, highlighting its essential role in bacterial fitness and potentially in virulence .

Host-Pathogen Interaction:

• While not directly about SHMT, Y. pseudotuberculosis is known to produce other virulence factors like the superantigen YPM that interacts with host immune cells, expanding T cells bearing specific V beta receptors in an MHC class II-dependent manner .

• The metabolic products of SHMT activity may influence the expression or function of these other virulence factors.

These observations collectively suggest that SHMT plays an indirect but significant role in Y. pseudotuberculosis pathogenesis by supporting metabolic requirements during infection and potentially influencing other virulence mechanisms.

What are the comparative characteristics of SHMT enzymes across different Yersinia species and other bacterial pathogens?

The comparative analysis of SHMT enzymes across different bacterial species reveals both conserved features and distinctive characteristics that may reflect specialized metabolic adaptations:

Sequence Homology and Structural Conservation:

*Estimated based on typical homology patterns between bacterial SHMTs

Enzymatic Properties:

*Estimated based on typical pH optima for bacterial SHMTs

Pathogenesis Relevance:

• In T. forsythia, glyA is directly associated with aggressive periodontitis .

• In S. aureus, glyA is responsible for lysostaphin resistance, demonstrating a role in antimicrobial defense .

• In most bacterial pathogens, glyA knockouts show growth defects, highlighting its essential metabolic role .

These comparative characteristics demonstrate that while SHMTs share core functional properties across bacterial species, they may have evolved specialized roles in different pathogens, potentially reflecting their adaptation to specific host environments and metabolic niches.

What novel applications or therapeutic targets might be developed based on Y. pseudotuberculosis SHMT research?

Research on Y. pseudotuberculosis SHMT opens several promising avenues for therapeutic and biotechnological applications:

Antimicrobial Development:

• SHMT inhibition represents a potential antimicrobial strategy given the enzyme's essential role in bacterial metabolism. Selective inhibitors that target structural differences between bacterial and human SHMT could offer new antibacterial agents with reduced side effects.

• Structure-based drug design approaches using the Y. pseudotuberculosis SHMT structure could guide the development of specific inhibitors.

• The fact that glyA knockouts show significant growth defects validates SHMT as an antimicrobial target .

Vaccine Development:

• Research on T. forsythia has identified glyA as a potential vaccine candidate for periodontal disease . Similar approaches could be explored for Y. pseudotuberculosis, particularly in combination with other virulence factors.

• Computational approaches for predicting putative vaccine candidates have been applied to priority pathogens and could be extended to Y. pseudotuberculosis SHMT .

Metabolic Engineering Applications:

• Understanding SHMT function in one-carbon metabolism could inform metabolic engineering strategies for:

  • Enhanced production of serine or glycine in industrial microbial strains

  • Development of auxotrophic strains for containment of genetically modified organisms

  • Creation of bacterial sensors for specific metabolites

Diagnostic Applications:

• Detection of glyA or SHMT activity could be incorporated into diagnostic tools for Y. pseudotuberculosis infections.

• The prevalence of glyA varies with disease severity in some bacterial infections (as seen with T. forsythia in periodontitis), suggesting potential as a prognostic marker .

These applications represent compelling research directions that could translate fundamental understanding of Y. pseudotuberculosis SHMT into practical interventions for infectious disease management and biotechnological innovation.

What are the current limitations in Y. pseudotuberculosis SHMT research and how might they be addressed?

Several significant challenges currently limit comprehensive understanding of Y. pseudotuberculosis SHMT, each requiring specific methodological approaches to overcome:

Technical Challenges:

• Protein Stability Issues: The recombinant Y. pseudotuberculosis SHMT requires careful handling to maintain stability. Researchers could address this by exploring alternative buffer formulations, fusion tag systems, or protein engineering approaches to enhance stability without compromising activity .

• Crystallization Difficulties: If structural studies have been challenging, alternative approaches such as cryo-electron microscopy, NMR for specific domains, or advanced computational modeling might provide structural insights when crystallization proves difficult.

Knowledge Gaps:

• Limited In Vivo Understanding: The role of SHMT in Y. pseudotuberculosis pathogenesis during actual infection remains understudied. Animal models of Y. pseudotuberculosis infection with wild-type and glyA mutant strains could address this gap.

• Regulatory Network Characterization: The regulation of glyA expression in Y. pseudotuberculosis under different environmental conditions is poorly understood. Transcriptomic and proteomic approaches examining glyA expression under various conditions relevant to infection would provide valuable insights.

Methodological Limitations:

• Assay Sensitivity: Current assays for SHMT activity may lack sensitivity for detecting subtle functional differences. Development of high-throughput, highly sensitive assays could accelerate research progress.

• Genetic Manipulation Challenges: If genetic manipulation of Y. pseudotuberculosis has been limiting, CRISPR-Cas9 or other advanced gene editing approaches could be optimized for this organism to facilitate more sophisticated genetic studies.

Addressing these limitations would significantly advance our understanding of Y. pseudotuberculosis SHMT and its role in bacterial metabolism and pathogenesis.

How might systems biology approaches enhance our understanding of Y. pseudotuberculosis SHMT in bacterial metabolism?

Systems biology approaches offer powerful frameworks for understanding Y. pseudotuberculosis SHMT within its broader metabolic and regulatory context:

Metabolic Flux Analysis:

• Use isotope-labeled substrates (e.g., ¹³C-serine) to trace carbon flow through SHMT-dependent pathways.

• Quantify flux distributions under different growth conditions using mass spectrometry.

• Develop computational models that predict metabolic responses to SHMT inhibition or overexpression.

• This approach would reveal how SHMT activity integrates with broader one-carbon metabolism and amino acid biosynthesis pathways.

Multi-omics Integration:

• Combine transcriptomics, proteomics, and metabolomics data from wild-type and glyA mutant strains.

• Identify compensatory mechanisms and regulatory networks that respond to altered SHMT activity.

• Apply network analysis to identify key regulatory nodes that control SHMT expression and activity.

• This integrated approach would provide a comprehensive view of how SHMT functions within the cellular network.

In Silico Modeling:

• Develop genome-scale metabolic models of Y. pseudotuberculosis that incorporate SHMT reactions.

• Perform in silico gene knockouts and flux balance analysis to predict phenotypic consequences.

• Simulate different environmental conditions to predict SHMT's role in adaptive responses.

• Validate model predictions with targeted experiments.

Host-Pathogen Interaction Modeling:

• Integrate bacterial metabolic models with host cell models to predict metabolic interactions during infection.

• Simulate the impact of SHMT activity on pathogen fitness in different host microenvironments.

• Identify potential metabolic vulnerabilities that could be targeted therapeutically.

These systems biology approaches would transform our understanding of SHMT from a single enzyme to a critical component within the complex adaptive system of bacterial metabolism and pathogenesis.

What emerging technologies could revolutionize research on bacterial SHMTs including Y. pseudotuberculosis?

Several cutting-edge technologies hold promise for transforming research on Y. pseudotuberculosis SHMT and related bacterial enzymes:

CRISPR-Based Technologies:

• CRISPRi/CRISPRa Systems: Enable precise control of glyA expression levels without completely deleting the gene, allowing study of dose-dependent effects.

• Base Editing: Introduce specific point mutations in glyA to study structure-function relationships without the need for traditional mutagenesis and selection.

• CRISPR Screens: Identify genetic interactions with glyA by performing genome-wide CRISPR screens in the presence of SHMT inhibitors or under conditions that stress one-carbon metabolism.

Advanced Structural Biology Methods:

• Cryo-Electron Microscopy: Determine high-resolution structures of SHMT complexes with substrates, inhibitors, or other protein partners without the need for crystallization.

• Time-Resolved X-ray Crystallography: Capture dynamic structural changes during the catalytic cycle using X-ray free-electron lasers.

• Integrative Structural Biology: Combine multiple structural techniques (X-ray, NMR, cryo-EM, SAXS) to build comprehensive models of SHMT in different functional states.

Single-Cell Technologies:

• Single-Cell RNA-Seq: Profile transcriptional heterogeneity in bacterial populations to understand variability in glyA expression.

• Single-Cell Metabolomics: Measure metabolite concentrations in individual bacterial cells to detect cell-to-cell variation in SHMT activity and its metabolic consequences.

• Spatial Transcriptomics: Map glyA expression patterns in infected tissues to understand its role during different stages of infection.

Synthetic Biology and Protein Engineering:

• Non-Canonical Amino Acid Incorporation: Engineer SHMT variants with novel functionalities or responsive elements.

• Directed Evolution: Develop SHMT variants with enhanced stability, altered substrate specificity, or resistance to inhibitors.

• Biosensors: Create SHMT-based biosensors for detecting metabolic states or screening for inhibitors.

These emerging technologies could dramatically accelerate research on bacterial SHMTs, providing unprecedented insights into their structure, function, regulation, and potential as therapeutic targets.